Abbott Labs Vs. Danaher: Abbott’s Everyday Products Beat Danaher’s Slumping Biotech Equipment
Abbott and Danaher both reported Q1 2026 results, but the businesses underneath those numbers point in opposite directions, and choosing the wrong one right now costs more than just a few percentage…
Read the full articleYou might also wanna read
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry pa
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Heartflow scales AI diagnostics while Iovance drives personalized cancer therapies, each faces unique financial and operational risks in 202
to the point: Healthcare & Life Sciences Q2/2026
......
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.
BPI's mid-year report highlights 2026 biotech trends
As we coast into July, BioProcess International looks back at some of the stories and enduring trends that defined the first half of 2026.
Comments
Sign in to join the conversation.
No comments yet. Be the first.